BioNTech, DualityBio Breast Cancer Drug Meets Phase 3 Trial Goal But Shows Higher Lung Disease Rate
(RTTNews) - On Monday, BioNTech (BNTX) and DualityBiologics, subsidiary of Duality Biotherapeutics (9606.HK) said trastuzumab pamirtecan met the primary endpoint in the Phase 3 DYNASTY-Breast02 trial, showing a statistically significant but modest improvement in progression-free
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
